Novo Nordisk’s Awiqli approval could change how basal insulin is used in type 2 diabetes
Novo Nordisk’s Awiqli wins FDA approval as the first once-weekly basal insulin. Read what this could change for type 2 diabetes care.
What Insulet’s EVOLUTION 2 data means for automated insulin delivery in type 2 diabetes
Insulet’s EVOLUTION 2 study shows 68% TIR with no boluses in type 2 diabetes. Analysis of what the FCL data means before the EVOLVE pivotal trial.